Eleusis Logo White


Private Company

Founded in 2013, Eleusis is one of the early movers in the psychedelic medicine space, with a two-pronged approach harnessing psychedelics for both anti-inflammatory and mental health applications.

Our strategic partnership with the Beckley Foundation is very important to Beckley Psytech as a company. We are lucky enough to be able to learn from more than 20 years of experience in psychedelic research. It’s not just the foundation’s scientific understanding about these compounds, it’s also their experience of navigating regulations to conduct research on controlled drugs, and the global network of academic collaborators that they have built up over the decades.


Eleusis was founded in 2013, and claims to be the first company in the world dedicated to transforming psychedelics into medicines.

We spoke to Shlomi Raz, CEO and Chairman of the Company, about his plans for Eleusis’ future.


WO2019079742A8  |  Methods and systems for enhancing safety of psychedelic drug therapies

Priority Date: 2017-10-19 |  Status: Published

General Subject Matter: Screening a candidate for treatment with psychedelic agent, including psilocybin

US20200147038A1  |   Assessing and treating psychedelic-responsive subjects

Priority Date: 2017-04-20 |  Status: Pending in US

General Subject Matter: Improving mental or physical well-being by administration of a psychedelic, including psilocybin

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.